Demasi Marco, Elia Angela, Simboli Giorgia Antonia, Moiraghi Alessandro, Paun Luca, Hudelist Benoit, Hamza Meissa, Schumacher Xavier, Trancart Bénédicte, Seneca Maimiti, Dezamis Edouard, Muto Jun, Chretien Fabrice, Oppenheim Catherine, Roux Alexandre, Zanello Marc, Pallud Johan
Service de Neurochirurgie, GHU-Paris Psychiatrie et Neurosciences, Paris , France.
Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, IMA-Brain, Paris , France.
Neurosurgery. 2025 Jan 29;97(2):399-409. doi: 10.1227/neu.0000000000003366.
The risk-to-benefit ratio of transopercular awake resection for recurrent insular diffuse gliomas is poorly studied. We assessed feasibility, safety, and efficacy of awake surgical resection of recurrent insular diffuse gliomas in patients with previous treatments (resection and/or radiotherapy and/or chemotherapy and/or combination).
Observational, retrospective, single-institution cohort analysis (2010-2023) of 123 consecutive adult patients operated on for an insular diffuse glioma (2021 World Health Organization classification) under awake conditions. Comparison between awake resection for an insular diffuse glioma as first-line treatment (n = 87) and after previous treatments (n = 36).
Function-based transopercular awake resection for a recurrent insular diffuse glioma (1) did not increase intraoperative adverse events compared with first-line resection; (2) was associated with a higher rate of intraoperative insufficient cooperation in patients with a previous combined oncological treatment (33.3%), compared with patients with a previous monotherapeutic modality (7.4%), and compared with patients with a first-line surgery (8.1%, P = .046); (3) resulted in resection rates similar to those of awake resection at first-line surgery (median 91.9%, vs 90.1%); (4) did not increase surgery-related complications or duration of hospital stay; (5) did not worsen the 6-month Karnofsky Performance Status score, seizure control, and sick leave; (6) did not influence the 6-month sick leave from work, but was associated with longer sick leave in patients with high-grade gliomas (38.0% vs 7.7%, P < .001).
Function-based transopercular awake resection seems feasible and safe at recurrence of a previously treated insular diffuse glioma, with similar resection rates and outcomes than first-time surgery.
经手术入路清醒状态下切除复发性岛叶弥漫性胶质瘤的风险效益比研究较少。我们评估了既往接受过治疗(手术切除和/或放疗和/或化疗和/或联合治疗)的复发性岛叶弥漫性胶质瘤患者进行清醒手术切除的可行性、安全性和有效性。
对2010年至2023年期间在清醒状态下接受岛叶弥漫性胶质瘤(2021年世界卫生组织分类)手术的123例连续成年患者进行观察性、回顾性、单机构队列分析。比较岛叶弥漫性胶质瘤作为一线治疗的清醒切除术(n = 87)和既往治疗后的清醒切除术(n = 36)。
复发性岛叶弥漫性胶质瘤基于功能的经手术入路清醒切除术:(1)与一线切除术相比,未增加术中不良事件;(2)与既往接受单一肿瘤治疗的患者(7.4%)和一线手术患者(8.1%,P = 0.046)相比,既往接受联合肿瘤治疗的患者术中合作不足率更高(33.3%);(3)切除率与一线手术清醒切除术相似(中位数91.9%对90.1%);(4)未增加手术相关并发症或住院时间;(5)未使6个月的卡氏功能状态评分、癫痫控制和病假情况恶化;(6)未影响6个月的工作病假,但与高级别胶质瘤患者更长的病假相关(38.0%对7.7%,P < 0.001)。
对于既往治疗过的岛叶弥漫性胶质瘤复发患者,基于功能的经手术入路清醒切除术似乎可行且安全,切除率和结局与首次手术相似。